Arena Pharmaceuticals Ltd.

Company Overview

Arena Pharmaceuticals is a global pharmaceutical company engaged in the discovery and development of transformational and novel medicines with optimized pharmacokinetics and pharmacology to patients globally.

Arena Pharmaceuticals has received an approval for the Lorcaserin drug for further marketing in South Korea and the U.S. for the management of weight-related disorders, such as obesity. The company’s medication up-and-comers in clinical development incorporate APD371 for pain, ralinepag for vascular diseases and APD334 for autoimmune diseases.

Arena’s restrictive pipeline incorporates different conceivably first or top-tier resources with expansive clinical utility. Etrasimod (APD334), with potential utility in a wide scope of inflammatory and immune conditions, is being assessed in later-stage clinical programs in Crohn’s disease (CD), ulcerative colitis (UC) and atopic dermatitis. Arena is also conducting clinical trials of olorinab medicine in Phase II with 12-week study to assess the adequacy and safety of olorinab medicine in irritable bowel syndrome (IBS) patients experiencing abdominal pain.

The company has entered into an agreement with Boehringer Ingelheim International GmbH to lead joint research to distinguish medication competitors focusing on G protein-coupled receptors GPCR, which has a place with the gathering of orphan central nervous system (CNS) receptors.

Arena Pharmaceuticals competes with GlaxoSmithKline Consumer Healthcare, Roche Group, VIVUS Inc., Novo Nordisk and Orexigen Therapeutics.

Company's Business Segments

• APIs : Arena Pharmaceuticals Source, Procure, Store, Supply High Quality APIs from their Global Network to meet complex regulatory needs.